AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31666344 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular remission
Number of subjects: 134
Study 31666344 — intervention group
Group type: EXPERIMENTAL
Intervention: No disease recurrence
Number of subjects: 134
Study 29888778 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yoghurt supplemented with rooster comb extract (RCE)
Number of subjects: 148
Study 26848185 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 4949
Study 26848185 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 4949
Study 24256500 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe economic loss (job or housing loss)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: COMPARATOR
Intervention: Moderate economic loss (loss of retirement savings, reduced work hours/wages, trouble paying rent/mortgage)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: EXPERIMENTAL
Intervention: Retirement loss, reduced hours/wages, and job loss (for women)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: EXPERIMENTAL
Intervention: Job loss and housing problems (for men)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial or complete job loss and housing problems (for middle-aged Americans)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of retirement savings (for older adults)
Number of subjects: 5382
Study 24256500 — intervention group
Group type: COMPARATOR
Intervention: Young adults (18 to 29)
Number of subjects: 5382
Study 22036059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal dexamethasone (8 mg) with intrathecal morphine (0.2 mg)
Number of subjects: 120
Study 22036059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution with intrathecal morphine 0.2 mg)
Number of subjects: 120
Study 20118683 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose priming with PHiD-CV
Number of subjects: 351
Study 20118683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose priming with PHiD-CV
Number of subjects: 351
Study 17397003 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiquimod 0.01% gel
Number of subjects: 0
Study 17397003 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 14697444 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M Cavilon No‐Sting Barrier Film
Number of subjects: 61
Study 14697444 — intervention group
Group type: COMPARATOR
Intervention: Sorbolene cream (10% glycerin)
Number of subjects: 61
Study 11943968 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills-based firearm safety program
Number of subjects: 70
Study 11943968 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 70
Study 9817336 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat biopsy screening
Number of subjects: 984
Study 9817336 — intervention group
Group type: COMPARATOR
Intervention: Primary biopsy screening
Number of subjects: 984
Study 8745496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometry technique (UFMI)
Number of subjects: 68
Study 8745496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorometry technique (UMI)
Number of subjects: 68
Study 8745496 — intervention group
Group type: COMPARATOR
Intervention: Group II (no MAS, but amniotic fluid with meconium stain)
Number of subjects: 68
Study 8745496 — intervention group
Group type: COMPARATOR
Intervention: Group III (normal control)
Number of subjects: 68
Study 2670647 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 tablet of 40 mg at night)
Number of subjects: 143
Study 2670647 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (2 tablets of 150 mg at night)
Number of subjects: 143
Study 2670647 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine and Ranitidine
Number of subjects: 143
Study 805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous procaine penicillin G, 4.8 million units IM in one session plus 1.0 g probenecide
Number of subjects: 327
Study 805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCI, 9 g over 4 days
Number of subjects: 327
Study 805649 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim, 80 mg-sulfamethoxazole, 400 mg (TMP-SMX) six tablets once daily for 3 days
Number of subjects: 327
Study 805649 — intervention group
Group type: EXPERIMENTAL
Intervention: TMP-SMX, six tablets twice on 1 day at a 6-hour interval
Number of subjects: 327
Study 31720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric nanobodies
Number of subjects: 0
Study 31720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic combinatorial library
Number of subjects: 0
Study 31720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Library clones
Number of subjects: 0
Study 31720928 — intervention group
Group type: EXPERIMENTAL
Intervention: Preliminary RD selection
Number of subjects: 0
Study 30371882 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Battlefield Acupuncture
Number of subjects: 233
Study 30371882 — intervention group
Group type: COMPARATOR
Intervention: Placebo Auricular Acupuncture
Number of subjects: 233
Study 30371882 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 233
Study 28945869 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (37.5 mg/d)
Number of subjects: 19
Study 25449342 — intervention group
Group type: EXPERIMENTAL
Intervention: CC with audio-visual feedback device
Number of subjects: 63
Study 25449342 — intervention group
Group type: COMPARATOR
Intervention: CC without audio-visual feedback device
Number of subjects: 63
Study 23219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing COC
Number of subjects: 34
Study 23219471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18477268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol (0.5 g x kg(‐1) in pump prime)
Number of subjects: 40
Study 18477268 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution (control)
Number of subjects: 40
Study 16302286 — intervention group
Group type: EXPERIMENTAL
Intervention: Eu‐glycaemic condition
Number of subjects: 8
Study 16302286 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycaemic condition
Number of subjects: 8
Study 15232337 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone alone
Number of subjects: 23
Study 15232337 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone in combination with clonazepam
Number of subjects: 23
Study 15232337 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam alone
Number of subjects: 23
Study 11382108 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feeding started in the 1st postoperative week
Number of subjects: 42
Study 11382108 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative oral feeding
Number of subjects: 42
Study 11382108 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of resection (extended laryngectomy with partial pharyngectomy)
Number of subjects: 42
Study 9203777 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 15 seconds
Number of subjects: 30
Study 9203777 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 30 seconds
Number of subjects: 30
Study 9203777 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% maleic acid etching for 60 seconds
Number of subjects: 30
Study 9203777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 8202968 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent infarct presence
Number of subjects: 1132
Study 8202968 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct size
Number of subjects: 1132
Study 8202968 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of silent infarcts
Number of subjects: 1132
Study 8202968 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with silent infarction
Number of subjects: 1132
Study 8202968 — intervention group
Group type: COMPARATOR
Intervention: Comparison with transient ischemic attacks
Number of subjects: 1132
Study 3118746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized atropine methonitrate (anticholinergic bronchodilator)
Number of subjects: 12
Study 3118746 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol hydrochloride (beta-adrenergic bronchodilator)
Number of subjects: 12
Study 29354934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage (1 min at one acupoint, once a day for 5 days, starting from the 3rd day after operation)
Number of subjects: 60
Study 29354934 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing after operation, guiding maternal breastfeeding and postpartum health education (Control group)
Number of subjects: 60
Study 29354934 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint massage
Number of subjects: 60
Study 27894521 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement
Number of subjects: 0
Study 27894521 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer
Number of subjects: 0
Study 27894521 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycarboxylate cement
Number of subjects: 0
Study 27894521 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment)
Number of subjects: 0
Study 26323489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 4 µg kg(‐1) (Group 2)
Number of subjects: 60
Study 26323489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 3 µg kg(‐1) (Group 1)
Number of subjects: 60
Study 26323489 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalytic iron (CI) levels at baseline
Number of subjects: 806
Study 23622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of CI levels
Number of subjects: 806
Study 23622911 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast nephropathy
Number of subjects: 806
Study 20568430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ling gui Ba fa and acupuncture at Neiguan (PC 6) and Taichong (LR 3)
Number of subjects: 60
Study 20568430 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture at Zusanli (ST 36), Zhongwan (CV 12), Taichong (LR 3), Neiguan (PC 6), Ganshu (BL 18) and Weishu (BL 21)
Number of subjects: 60
Study 18156544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-mouth ventilation
Number of subjects: 70
Study 18156544 — intervention group
Group type: COMPARATOR
Intervention: Mouth-to-mask ventilation
Number of subjects: 70
Study 18156544 — intervention group
Group type: COMPARATOR
Intervention: Mouth-to-face shield ventilation
Number of subjects: 70
Study 17008362 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV behavioural intervention
Number of subjects: 1295
Study 14521248 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 197
Study 14521248 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 197
Study 14521248 — intervention group
Group type: COMPARATOR
Intervention: No-attention control
Number of subjects: 197
Study 11127760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate / 10 microg ethinyl estradiol
Number of subjects: 219
Study 11127760 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate / 5 microg ethinyl estradiol
Number of subjects: 219
Study 11127760 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg norethindrone acetate / 2.5 microg ethinyl estradiol
Number of subjects: 219
Study 11127760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 8694219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration with diclofenac before surgery
Number of subjects: 100
Study 8694219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration with diclofenac after surgery
Number of subjects: 100
Study 8694219 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 100
Study 8694219 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac before surgery
Number of subjects: 100
Study 8694219 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac after surgery
Number of subjects: 100
Study 1534716 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 97
Study 1534716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine retard (20 mg twice daily)
Number of subjects: 97
Study 1534716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 2412034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (120 mg/day)
Number of subjects: 14
Study 2412034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31364875 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic powder containing Lactobacillus reuteri (108 CFU) and soluble fiber (4.3 g)
Number of subjects: 20
Study 31364875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29405863 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminar on Compassion
Number of subjects: 41
Study 29405863 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 41
Study 28088806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe sterol-supplemented yogurt
Number of subjects: 64
Study 28088806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24559600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger capsules
Number of subjects: 150
Study 24559600 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate capsules
Number of subjects: 150
Study 24559600 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 150
Study 22356799 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (N = 50)
Number of subjects: 100
Study 22356799 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 50)
Number of subjects: 100
Study 20134179 — intervention group
Group type: EXPERIMENTAL
Intervention: Compoglass F
Number of subjects: 98
Study 20134179 — intervention group
Group type: COMPARATOR
Intervention: Twinky Star
Number of subjects: 98
Study 18494974 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation only (Group 3)
Number of subjects: 30
Study 18494974 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation (diamond bur + 37% phosphoric acid) (Group 1)
Number of subjects: 30
Study 18494974 — intervention group
Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser irradiation + 37% phosphoric acid (Group 2)
Number of subjects: 30
Study 15889546 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel red lesion detection method based on pixel classification and k-nearest neighbor classifier
Number of subjects: 0
Study 15889546 — intervention group
Group type: COMPARATOR
Intervention: Comparison with several different automatic systems
Number of subjects: 0
Study 15889546 — intervention group
Group type: COMPARATOR
Intervention: Performance comparison with human expert
Number of subjects: 0
Study 12366625 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training in strategies to rise from the floor (n = 17, mean age 81)
Number of subjects: 35
Study 12366625 — intervention group
Group type: COMPARATOR
Intervention: Control chair-based flexibility intervention (n = 18, mean age 80)
Number of subjects: 35
Study 12366625 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual training in strategies to rise from the floor
Number of subjects: 35
Study 12366625 — intervention group
Group type: COMPARATOR
Intervention: Control chair-based flexibility intervention
Number of subjects: 35
Study 10426244 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 204
Study 10426244 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 204
Study 7538703 — intervention group
Group type: EXPERIMENTAL
Intervention: HCR therapy (hyperthermia combined with chemotherapy and irradiation)
Number of subjects: 243
Study 7538703 — intervention group
Group type: COMPARATOR
Intervention: CR therapy (chemo-radiotherapy)
Number of subjects: 243
Study 7538703 — intervention group
Group type: EXPERIMENTAL
Intervention: HCR therapy
Number of subjects: 243
Study 7538703 — intervention group
Group type: COMPARATOR
Intervention: CR therapy
Number of subjects: 243
Study 2185968 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide injections (100 micrograms t.i.d.)
Number of subjects: 16
Study 2185968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 498909 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 51
Study 498909 — intervention group
Group type: COMPARATOR
Intervention: Meglumine ioxithalamate
Number of subjects: 51
Study 30679336 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 13 mg with intrathecal fentanyl 20 µg (Group BF)
Number of subjects: 56
Study 30679336 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 13 mg (Group B)
Number of subjects: 56
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application used as a job aid to ASHAs to increase coverage of MNCH services.
Number of subjects: 11
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application used as a job aid to ASHAs and Auxiliary Nurse Midwives (ANMs) for complicated cases.
Number of subjects: 11
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Web interface as a job aid for medical officers and PHC staff.
Number of subjects: 11
Study 28599674 — intervention group
Group type: COMPARATOR
Intervention: Usual practice in the control area where the current level of services provided by the government will continue.
Number of subjects: 11
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite index of critical, proven MNCH services.
Number of subjects: 11
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of neonates visited by ASHAs at home within the first week of birth.
Number of subjects: 11
Study 28599674 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage of selected MNCH services and care sought by complicated cases.
Number of subjects: 11
Study 26074359 — intervention group
Group type: EXPERIMENTAL
Intervention: LT + IP (n = 6)
Number of subjects: 13
Study 26074359 — intervention group
Group type: COMPARATOR
Intervention: LT (n = 7)
Number of subjects: 13
Study 23719149 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cardiac rehabilitation (CR) with dietary counseling
Number of subjects: 62
Study 23719149 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonrehabilitation)
Number of subjects: 62
Study 21235787 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.05 mg/d
Number of subjects: 435
Study 21235787 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin 0.15 mg/d
Number of subjects: 435
Study 21235787 — intervention group
Group type: EXPERIMENTAL
Intervention: rostafuroxin (combined dosage arms)
Number of subjects: 435
Study 21235787 — intervention group
Group type: COMPARATOR
Intervention: rostafuroxin and placebo (combined)
Number of subjects: 435
Study 19208731 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g EAA/d for 3 months (supplemented treatment group)
Number of subjects: 14
Study 19208731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 14
Study 17536125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio nut diet (15% of daily caloric intake)
Number of subjects: 15
Study 10819701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine hydrochloride, 0.1 mg/d
Number of subjects: 194
Study 10819701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 8632299 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg) preceded by ketoconazole
Number of subjects: 0
Study 8632299 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.125 mg) preceded by placebo
Number of subjects: 0
Study 1360479 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 9
Study 6700072 — intervention group
Group type: EXPERIMENTAL
Intervention: EMT defibrillation combined with paramedic care
Number of subjects: 540
Study 6700072 — intervention group
Group type: COMPARATOR
Intervention: Basic EMT and paramedic care
Number of subjects: 540
Study 31518978 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol, 540,000 IU)
Number of subjects: 267
Study 30646039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice arm
Number of subjects: 4774
Study 30646039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active choice with peer comparison arm
Number of subjects: 4774
Study 30646039 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm
Number of subjects: 4774
Study 26898705 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-step model for recruitment to RCTs
Number of subjects: 60
Study 24882450 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose beverage
Number of subjects: 0
Study 24882450 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0
Study 24882450 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-depleted participants
Number of subjects: 0
Study 22245724 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax drink (2.5 g of soluble fibers)
Number of subjects: 44
Study 22245724 — intervention group
Group type: EXPERIMENTAL
Intervention: Flax tablets (2.5 g of soluble fibers)
Number of subjects: 44
Study 22245724 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (300 mL drink)
Number of subjects: 44
Study 19914563 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments including surgery, chemotherapy, molecular therapy, radiation therapy, immunotherapy, and palliative therapy
Number of subjects: 107
Study 18401903 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin 20 mg twice a day along with topical clindamycin (1%) and adapalene (0.1%) for 24 weeks
Number of subjects: 60
Study 18401903 — intervention group
Group type: COMPARATOR
Intervention: Oral isotretinoin only
Number of subjects: 60
Study 16463825 — intervention group
Group type: EXPERIMENTAL
Intervention: Licox
Number of subjects: 7